Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma

Immune checkpoint inhibitors (ICI) have improved survival of patients with metastatic melanoma but can induce autoimmunologic side effects. Ye et al. report a retrospective analysis that further supports the finding that these are biomarkers for patients’ clinical benefit. Thereby, patients with imm...

Descripción completa

Detalles Bibliográficos
Autor principal: Hassel, Jessica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770793/
https://www.ncbi.nlm.nih.gov/pubmed/34697417
http://dx.doi.org/10.1038/s41416-021-01390-1
_version_ 1784635445344206848
author Hassel, Jessica C.
author_facet Hassel, Jessica C.
author_sort Hassel, Jessica C.
collection PubMed
description Immune checkpoint inhibitors (ICI) have improved survival of patients with metastatic melanoma but can induce autoimmunologic side effects. Ye et al. report a retrospective analysis that further supports the finding that these are biomarkers for patients’ clinical benefit. Thereby, patients with immune-related adverse events show a differential gene expression in chemokine-mediated signalling.
format Online
Article
Text
id pubmed-8770793
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87707932022-02-04 Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma Hassel, Jessica C. Br J Cancer Editorial Immune checkpoint inhibitors (ICI) have improved survival of patients with metastatic melanoma but can induce autoimmunologic side effects. Ye et al. report a retrospective analysis that further supports the finding that these are biomarkers for patients’ clinical benefit. Thereby, patients with immune-related adverse events show a differential gene expression in chemokine-mediated signalling. Nature Publishing Group UK 2021-10-25 2022-02-01 /pmc/articles/PMC8770793/ /pubmed/34697417 http://dx.doi.org/10.1038/s41416-021-01390-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Editorial
Hassel, Jessica C.
Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title_full Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title_fullStr Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title_full_unstemmed Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title_short Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
title_sort checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770793/
https://www.ncbi.nlm.nih.gov/pubmed/34697417
http://dx.doi.org/10.1038/s41416-021-01390-1
work_keys_str_mv AT hasseljessicac checkpointblockerinducedautoimmunityasanindicatorfortumourefficacyinmelanoma

Ejemplares similares